EXPLANATORY STATEMENT
NATIONAL HEALTH ACT 1953
NATIONAL HEALTH (EFFICIENT FUNDING OF CHEMOTHERAPY) SPECIAL ARRANGEMENT AMENDMENT INSTRUMENT 2016 (No. 8)
PB 68 of 2016
Authority
Subsection 100(1) of the National Health Act 1953 (the Act) enables the Minister to make special arrangements for the supply of pharmaceutical benefits. Subsection 100(2) of the Act provides that the Minister may vary or revoke a special arrangement made under subsection 100(1).
Subsection 100(3) of the Act provides that Part VII of the Act, and instruments made for the purposes of Part VII, have effect subject to a special arrangement made under subsection 100(1).
Purpose
The purpose of this legislative instrument, made under subsections 100(1) and 100(2) of the Act, is to amend the National Health (Efficient Funding of Chemotherapy) Special Arrangement 2011 (PB 79 of 2011) (the Special Arrangement), to make changes relating to the efficient funding of chemotherapy.
The Special Arrangement achieves greater efficiency in payment for the supply of injected or infused chemotherapy medicines (‘chemotherapy pharmaceutical benefits’) to eligible patients being treated for cancer, to reflect the 2010 budget measure entitled ‘Revised arrangements for the efficient funding of chemotherapy drugs’. This Special Arrangement also relates to the supply of medicines associated with the side-effects of cancer and cancer treatment (‘related pharmaceutical benefits’) at certain public hospitals.
This instrument makes changes to the pharmaceutical benefits available under the Special Arrangement for the efficient funding of chemotherapy. These changes reflect changes made to the National Health (Listing of Pharmaceutical Benefits) Instrument 2012 made under sections 84AF, 84AK, 85, 85A, 88 and 101 of the Act, which commence on the same day.
This instrument:
- removes the brands ‘Carboplatin Kabi’ for the listed drug ‘Carboplatin; ‘Epirubicin Kabi’ for the listed drug ‘Epirubicin’; ‘Gemcitabine Kabi’ for the listed drug ‘Gemcitabine’; ‘Ondansetron Kabi’ for the listed drug ‘Ondanstron’; ‘Oxaliplatin Kabi’ for the listed drug ‘Oxaliplatin’; ‘Topotecan Kabi’ for the listed drug ‘Topotecan’; ‘Vinorelbine Kabi’ for the listed drug ‘Vinorelbine’;
- adds the brands ‘PEMETREXED-DRLA’ and ‘Tevatrexed’ for the listed drug ‘Pemetrexed’;
- amends the circumstance codes and associated circumstances and purpose codes and associated purposes for the listed drug ‘Rituximab’; and
- adds a new responsible person ‘Teva Pharma Australia Pty Limited (TB)’.
A provision by provision description of this instrument is contained in Attachment.
Consultations
An ongoing and formal process of consultation in relation to matters relevant to the Special Arrangement includes the involvement of interested parties through the membership of the Pharmaceutical Benefits Advisory Committee (PBAC). PBAC is an independent expert body established by section 100A of the Act which makes recommendations to the Minister about which drugs and medicinal preparations should be available as pharmaceutical benefits.
PBAC members are appointed following nomination by prescribed organisations and associations from consumers, health economists, practising community pharmacists, general practitioners, clinical pharmacologists and specialists, with at least one member selected from each of those interests or professions. Remaining members are persons whom the Minister is satisfied have qualifications and experience in a field relevant to the functions of PBAC, and that would enable them to contribute meaningfully to the deliberations of PBAC. When recommending the listing of a medicine on the Pharmaceutical Benefits Scheme (PBS), PBAC takes into account the medical conditions for which the medicine has been approved for use in Australia, its clinical effectiveness, safety and cost-effectiveness compared with other treatments.
This instrument commences on 1 August 2016.
This instrument is a legislative instrument for the purposes of the Legislation Act 2003.
ATTACHMENT
PROVISION BY PROVISION DESCRIPTION OF THE NATIONAL HEALTH (EFFICIENT FUNDING OF CHEMOTHERAPY) SPECIAL ARRANGEMENT AMENDMENT INSTRUMENT 2016 (No. 8)
Section 1 Name of Instrument
This section provides that this Instrument is the National Health (Efficient Funding of Chemotherapy) Special Arrangement Amendment Instrument 2016 (No. 8) and that it may also be cited as PB 68 of 2016.
Section 2 Commencement
This section provides that this Instrument commences on 1 August 2016.
Section 3 Amendments to PB 79 of 2011
This section amends the National Health (Efficient Funding of Chemotherapy) Special Arrangement 2011 (PB 79 of 2011) (the Special Arrangement).
Item 1 amends the entry in Schedule 1 Part 1 of the Special Arrangement for the listed drug ‘Carboplatin’ by removing the pharmaceutical benefit which is the listed drug ‘Carboplatin’ in the form ‘Solution for I.V. injection 450 mg in 45 mL’ and brand ‘Carboplatin Kabi’.
Item 2 amends the entry in Schedule 1 Part 1 of the Special Arrangement for the listed drug ‘Epirubicin’ by removing the pharmaceutical benefit which is the listed drug ‘Epirubicin’ in the form ‘Solution for injection containing epirubicin hydrochloride 200 mg in 100 mL’ and brand ‘Epirubicin Kabi’.
Item 3 amends the entry in Schedule 1 Part 1 of the Special Arrangement for the listed drug ‘Gemcitabine’ by removing the pharmaceutical benefit which is the listed drug ‘Gemcitabine’ in the form ‘Powder for I.V. infusion 1 g (as hydrochloride)’ and brand ‘Gemcitabine Kabi’.
Item 4 amends the entry in Schedule 1 Part 1 of the Special Arrangement for the listed drug ‘Oxaliplatin’ by removing the pharmaceutical benefit which is the listed drug ‘Oxaliplatin’ in the form ‘Solution concentrate for I.V. infusion 100 mg in 20 mL’ and brand ‘Oxaliplatin Kabi’.
Item 5 amends the entry in Schedule 1 Part 1 of the Special Arrangement for the listed drug ‘Pemetrexed’ by adding a new pharmaceutical benefit which is the listed drug ‘Pemetrexed’ in the form ‘Powder for I.V. infusion 100 mg (as disodium)’ and the brand ‘PEMETREXED‑DRLA’.
Item 6 amends the entry in Schedule 1 Part 1 of the Special Arrangement for the listed drug ‘Pemetrexed’ by adding new pharmaceutical benefits which is the listed drug ‘Pemetrexed’ in the forms ‘Powder for I.V. infusion 100 mg (as disodium)’ and ‘Powder for I.V. infusion 500 mg (as disodium)’ and the brand ‘Tevatrexed’.
Item 7 amends the entry in Schedule 1 Part 1 of the Special Arrangement for the listed drug ‘Pemetrexed’ by adding a new pharmaceutical benefit which is the listed drug ‘Pemetrexed’ in the form ‘Powder for I.V. infusion 1 g (as disodium)’ and the brand ‘PEMETREXED-DRLA’.
Item 8 amends the entry in Schedule 1 Part 1 of the Special Arrangement for the listed drug ‘Pemetrexed’ by adding a new pharmaceutical benefit which is the listed drug ‘Pemetrexed’ in the form ‘Powder for I.V. infusion 1 g (as disodium)’ and the brand ‘Tevatrexed’.
Item 9 amends the entry in Schedule 1 Part 1 of the Special Arrangement for the listed drug ‘Rituximab’ in each of the forms ‘Solution for I.V. infusion 500 mg in 50 mL’ and ‘Solution for I.V. infusion 100 mg in 10 mL’ by removing all instances of the circumstance code ‘C6187’ and adding the new circumstance code ‘C6309’.
Item 10 amends the entry in Schedule 1 Part 1 of the Special Arrangement for the listed drug ‘Topotecan’ by removing the pharmaceutical benefit which is the listed drug ‘Topotecan’ in the form ‘Powder for I.V. infusion 4 mg (as hydrochloride)’ and brand ‘Topotecan Kabi’.
Item 11 amends the entry in Schedule 1 Part 1 of the Special Arrangement for the listed drug ‘Vinorelbine’ by removing the pharmaceutical benefit which is the listed drug ‘Vinorelbine’ in the form ‘Solution for I.V. infusion 50 mg (as tartrate) in 5 mL’ and brand ‘Vinorelbine Kabi’.
Item 12 amends the entry in Schedule 1 Part 2 of the Special Arrangement for the listed drug ‘Rituximab’ by removing the purpose code ‘P6187’; and adding the new purpose code ‘P6309’.
Item 13 amends the entry in Schedule 2 of the Special Arrangement for the listed drug ‘Ondansetron’ in the forms ‘I.V. injection 4 mg (as hydrochloride dehydrate) in 2 mL’ and ‘I.V. injection 8 mg (as hydrochloride dehydrate) in 4 mL’ by removing the brand ‘Ondansetron Kabi’.
Item 14 amends the entry in Schedule 2 of the Special Arrangement for the listed drug ‘Rituximab’ in the form ‘Solution for subcutaneous injection containing rituximab 1400 mg in 11.7 mL’ by removing circumstance code ‘C6187’ (all instances) and purpose code ‘P6187’; and adding circumstance code ‘C6317’ and purpose code ‘P6317’.
Item 15 amends the entry in Schedule 3 of the Special Arrangement by adding a new responsible person Teva Pharma Australia Pty Limited (TB).
Item 16 amends the entry in Schedule 4 of the Special Arrangement for the listed drug ‘Rituximab’ by removing the circumstance code ‘C6187’ and purpose code ‘P6187’ and their associated circumstances; and adding the new circumstance codes ‘C6309’ and ‘C6317’ and purpose codes ‘P6309’ and ‘P6317’ and their associated circumstances.
Statement of Compatibility with Human Rights
Prepared in accordance with Part 3 of the Human Rights (Parliamentary Scrutiny) Act 2011
National Health (Efficient Funding of Chemotherapy) Special Arrangement Amendment Instrument 2013 (No. 4)
This Legislative Instrument is compatible with the human rights and freedoms recognised or declared in the international instruments listed in section 3 of the Human Rights (Parliamentary Scrutiny) Act 2011.
Overview of the Legislative Instrument
The purpose of this legislative instrument, made under subsections 100(1) and 100(2) of the Act, is to amend the National Health (Efficient Funding of Chemotherapy) Special Arrangement 2011 (PB 79 of 2011) (the Special Arrangement), to make changes to the special arrangement relating to the efficient funding of chemotherapy.
The Special Arrangement achieves greater efficiency in payment for the supply of injected or infused chemotherapy medicines (‘chemotherapy pharmaceutical benefits’) to eligible patients being treated for cancer, to reflect the 2010 budget measure titled ‘Revised arrangements for the efficient funding of chemotherapy drugs’. This Special Arrangement also relates to the supply of medicines associated with the side-effects of cancer and cancer treatment (‘related pharmaceutical benefits’) at certain public hospitals.
This Instrument:
- adds 4 new listed brands for the listed drugs ‘Doxorubicin’, and ‘Gemcitabine’;
- adds 1 new listed form for the listed drug ‘Aprepitant’;
- removes 2 listed brands for the listed drug ‘Docetaxel’; and
- adds new circumstance codes and the associated circumstances for the listed drug ‘Aprepitant’.
Human rights implications
This legislative instrument engages Article 2 and 12 of the International Covenant on Economic, Social and Cultural Rights (ICESCR) by assisting with the progressive realisation by all appropriate means of the right of everyone to the enjoyment of the highest attainable standard of physical and mental health.
The Pharmaceutical Benefits Scheme (PBS) is a benefit scheme which assists with advancement of this human right by providing for subsidised access by patients to medicines. The recommendatory role of the Pharmaceutical Benefits Advisory Committee (PBAC) ensures that decisions about subsidised access to medicines on the PBS are evidence-based.
Conclusion
This Legislaive Instrument is compatible with human rights because it advances the protection ohuman rights.